Adocia Sa · EURONEXT:ADOC
Adocia Sa — Investor Presentation (October 2023)
42 slides from Adocia Sa's investor presentation, October 2023
Slide 1: Corporate Presentation
Corporate Presentation October 2023
Slide 2: Forward-looking statements
Forward-looking statements This corporate presentation (the “Presentation”) has been prepared by ADOCIA S.A. (the “Company” and, together with its subsidiary, the “Group”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall mean a
Slide 3: Adocia at a glance
Adocia at a glance 1 Mission: Development of innovative formulations of approved peptides and novel cell therapy approaches for diabetes and obesity 2 Business model: Licensing-out/Partnering our products and technologies after proof-of-concept in animal and/or human model 2 partnerships with large
Slide 4: Highly experienced management team
Highly experienced management team Gérard Soula Olivier Soula Valérie PhD, MBA PhD, MBA Danaguezian President CEO Chief Financial Officer Co-founder Co-founder Jérémy Benattar Rosy Eloy PharmD, Eng MD Marketing & Strategy Chief Medical Officer Director • Co-founded by Gérard, Olivier and Rémi Soula
Slide 5: Business Strategy: solid partnerships and promising projects
Business Strategy: solid partnerships and promising projects Partnerships: BC Lispro & BC Combo M1Pram Agreements on 3 products Future milestones (80M$) + royalties Exclusive negotiation rights in view with pharma leaders in of a global partnership insulins Proprietary Products to BC Lispro be licen
Slide 6: A diversified specialty products pipeline
A diversified specialty products pipeline Preclinic Phase 1 Phase 2 Phase 3 Status / Upcoming milestones Partner Phase 3 in China ongoing Diabetes BC Lispro Ultra-Rapid Insulin Phase 3 in USA and Europe ready to start* Insulins Combination Phases 1 completed – Preparation of Asia & other territories
Slide 7: Partnering models based on proprietary technology platforms with strong IP strategy
Adocia’s partnering models are based on proprietary technology platforms with strong IP strategy BioChaperone® AdOral® AdoShell® AdoGel® • Pharmaceutical excipient • Pharmaceutical excipient • Hydrogel scaffold • Biomaterial • Forms a complex with • Enhances peptides oral route • Cells encapsulation
Slide 8: Diabetes and Obesity: worldwide chronic pandemics
Diabetes and Obesity: worldwide chronic pandemics 537 million people live with diabetes1 Diabetes is closely linked to obesity 1 in 11 • In the US, 65% of adults with type 13 diabetes, and 85% of type 24 are overweight or obese, making DIABESITY a new pandemic 1.9 billion are overweight or obese2 IN
Slide 9: Proprietary specialty products based on approved drugs
Proprietary specialty products based on approved drugs 9 9
Slide 10: BioChaperone Lispro
BioChaperone® Lispro Ultra-Rapid Acting Insulin for a tighter glycemic control 10 10
Slide 11: BC Lispro has competitive advantages in the Ultra-Rapid Insulin class
BC Lispro has competitive advantages in the Ultra-Rapid Insulin class Post-meal glycaemia in T1D • Better efficacy profile for less hyperglycemia and less hypoglycemia (“Faster-in” / “Faster-out”) vs. comparators AUC0-2h: -61%* • Good tolerance for optimized daily use • Range of strengths (U100 & U2
Slide 12: BC Lispro in phase 3 program in China with Tonghua Dongbao
BC Lispro in phase 3 program in China with Tonghua Dongbao Market • Insulin and analogs in China: c. $4 billion Partnership with Tonghua Dongbao (2018) • Licensed for development & commercialization for China and other Asian territories2: • $10m upfront • $ 5m milestone - 1st patient on the Phase 3
Slide 13: BC Combo, glargine-lispro premix
BC Combo, glargine-lispro premix The best insulin premix 13 13
Slide 14: BC Combo, a unique combination of glargine and lispro
BC Combo, a unique combination of glargine and lispro, the gold standards of basal and prandial insulins BioChaperone® Combo 1 product Once or twice a day U200 fixed ratio (150 U/mL glargine - 50 U/mL Less hyperglycemia lispro) Simple Affordable Less hypoglycemia Limited number of injections
Slide 15: BC Combo is licensed to Tonghua Dongbao in China
BC Combo is licensed to Tonghua Dongbao in China Premix market Tonghua Dongbao deal $2.7bn1 Western Markets: T2D patients • $40m upfront $2.3bn1 • $50m upcoming development milestones Emerging Markets: • Next milestone: $10m to be received T1D & T2D at start of Phase 3 ~65% patients Market share in
Slide 16: M1Pram Insulin & Amylin analogs combination
M1Pram Insulin & Amylin analogs combination Breakthrough treatment to address the unmet medical need of overweight patients living with diabetes 16 16
Slide 17: Agreement with Sanofi on M1Pram
Agreement with Sanofi on M1Pram On July 5, 2023, • Adocia received €10m payment from Sanofi in exchange of an exclusive negotiation right on M1Pram • Sanofi commitment will contribute to accelerate M1Pram clinical development • Sanofi agreement covers any programs related to insulin / pramlintide co
Slide 18: M1Pram, a bi-hormonal therapy to treat people with obesity and diabetes
M1Pram, a bi-hormonal therapy to treat people with obesity and diabetes Higher risk of co-morbidities Obesity Diabetes Amylin Analog Insulin Analog Pramlintide M1 To control weight To control glycemia Insulin causes weight gain Obesity is a main concern for patients under intensive insulin therapy,
Slide 19: Amylin is missing in people with insulin-dependent diabetes
Amylin is missing in people with insulin-dependent diabetes, and it contributes to diabetes dysregulations Meal Insulin Normal pattern Amylin exerts important physiological effects on Level of secretion metabolism and weight control (relative scale) Amylin Glucagon 1. Activates amylin receptors in d
Slide 20: M1Pram reduces body weight with high efficacy in T1D with obesity
M1Pram reduces body weight with high efficacy in T1D with obesity CT041 : Phase 2 study – M1Pram vs. lispro (Humalog®) - type 1 diabetes - 16 weeks ambulatory Body Weight Change from Baseline to Week 16 All patients BMI ≥ 25 kg/m² BMI ≥ 30 kg/m2 (p value = 0.001) (post hoc, p value = 0.03) Mean +/-
Slide 21: Body weight loss with M1Pram comparable with insulin plus Semaglutide or Tirzepatide
Body weight loss with M1Pram in T1D is comparable with insulin plus Semaglutide or Tirzepatide treatment in T2D Change from baseline in body weight at W16 Semaglutide - 4.55 kg vs. - 1.08 kg Tirzepatide - 5.6 kg vs. + 0.4 Kg T2D taking basal insulin T2D taking glargine Mean BMI 32 kg/m2 [19-51] Mean
Slide 22: Maintained glycemic control, with 21% reduction in prandial insulin dose
Maintained glycemic control, with 21% reduction in prandial insulin dose Change from baseline* Mean (SD) P-value M1Pram Lispro HbA1c (%) 0.14 (0.51) 0.10 (0.51) 0.81 (NS) Time-In-Range 70-180 mg/dL (%) -3.17 (8.76) -1.54 (8.87) 0.29 (NS) Prandial insulin dose (U/d) -5.97(6.18) -0.61(7.08) <0.001 Whi
Slide 23: Medical value of M1Pram is confirmed
Medical value of M1Pram is confirmed ✓ Significant weight loss demonstrated & satiety effect ✓ Glycemic control maintained, without increase of hypoglycemia ✓ Sparing effect on prandial insulin dose ✓ Product well tolerated and safe ✓ Easy-to-use: one product injected at mealtime ✓ Excellent patient
Slide 24: M1Pram generates high expectations from KOLs
M1Pram generates high expectations from KOLs “The phase 2 study of M1Pram shows that a single injection “The glycemic results with M1Pram (P1b) are with each meal is as easy to use and as efficient as Humalog quite promising as is the observed weight loss, for glycemic control without increasing the
Slide 25: AdoShell Islets
AdoShell® Islets Immunoprotective scaffold for islets of Langerhans transplantation to cure Type 1 Diabetes 25 25
Slide 26: Islets transplantation has many limitations
Islets transplantation has changed lives of patients living with unstable diabetes, but it still has many limitations • Among 40 million people living with T1D worldwide, 75 000 have a form particularly unstable (sometimes called “brittle”) • Life expectancy 27- to 45-year-old • Approx. 1,000 cases
Slide 27: AdoShell, an immuno-protective scaffold for islets transplantation
AdoShell®, an immuno-protective scaffold for islets of Langerhans transplantation for diabetes Hydrogel Reagents Immuno-isolation AdoShell Islets Ab, T cells Large entities > 10 nm + Insulin secreting cells • 1st generation: islets of Langerhans from deceased donors Free diffusion • 2nd generation:
Slide 28: AdoShell: An ultra-thin, immuno-protective hydrogel film
AdoShell® : An ultra-thin, immuno-protective hydrogel film for cells encapsulation High water content for cell compatibility ✓ Immuno-isolating gel ✓ Ultra-thin aseptic film ✓ High cell density for miniaturization ✓ Biocompatible ✓ Mechanically resistant ✓ Implantable by mini-invasive surgery ✓ Retr
Slide 29: POC in diabetic rat: glycemia controlled during a 132-day study
POC in diabetic rat: glycemia controlled during a 132-day study without immunosuppressor 1. Transplantation of AdoShell containing allogenic islets in diabetic rat peritoneum at day 0 2. Explantation of the implant at day 132. Sacrifice of control group at day 35 Glycemia Body Weight Insulin Transpl
Slide 30: AdoShell provides a platform, opening to many cell therapy markets
AdoShell provides a platform, opening to many cell therapy markets • AdoShell scaffold displays key attributes enabling to progress towards new and more effective cell therapies: ✓ No need of immunosuppressors • No need of gene-editing strategy for immune-evasive iPSCs ✓ Safe and efficient cell engr
Slide 31: AdOral
AdOral® A promising technology for oral delivery of peptides 31 31
Slide 32: Only 5 peptide therapeutics approved for oral delivery in a growing market
Only 5 peptide therapeutics have been approved for oral delivery in a growing market dominated by injectable forms Global Peptide Therapeutics Market* ($) *mAb excluded from the analysis Cyclosporin 39 Billion 48 Billion 1.2 kDa Approved 1995 Voclosporin Octreotide 50 Desmopressin 1.2 kDa 1.0 kDa GL
Slide 33: AdOral: a promising technology for oral delivery of peptides
AdOral: a promising technology for oral delivery of peptides AdOral is a unique formulation based on a new type of permeation enhancer (PE) combined with peptide protection against degradation Technology patented until 2042 globally The technology has been validated with Semaglutide compared to Rybe
Slide 34: Semaglutide formulated with AdOral shows improved bioavailability in animal
Semaglutide formulated with AdOral has shown significantly improved bioavailability in animal Median Semaglutide PK Profile (N=10) Bioavailability of semagludide Rybelsus® formulated with AdOral: AdOral - semaglutide 5-fold higher median than Rybelsus Adocia seeks to establish proof of concept with
Slide 35: AdoGel
AdoGel® Long-acting drug delivery platform 35 35
Slide 36: AdoGel, a biomaterial for ultra long delivery of therapeutic agents
AdoGel, a biomaterial for ultra long delivery of therapeutic agents Adocia is developing a soft tissue-like biomaterial for sustained release of small molecules/biologics • Pharmaceutic forms • Implantable & Removable device • Injectable (in-situ forming gel) • Main properties Implantable device Inj
Slide 37: Sustained release of Levonorgestrel over 180 days in animal model
First application: sustained release of Levonorgestrel (LNG) over 180 days after SC administration in animal model Mean (±SE) PK profile Cumulative absorption No initial burst Pseudo-zero order AdoGel Preclinical proof of concept is ongoing with LNG Additional showcase studies are also ongoing with
Slide 38: Financial & news flow
Financial & news flow Kis} ADOCIA f-
Slide 39: News flow
News flow BC Lispro M1Pram and related projects AdoShell® Islets • In China (with partner THDB): Phase 3 • Exclusive negotiation rights • First-in-human study ongoing granted to Sanofi in view of a preparation in 2023 • Phase 3 completion expected 2024 global partnership • $10m milestones payment Ad
Slide 40: Key financials & shareholder information
Key financials & shareholder information Key financials features Shareholder ownership Market information As of Oct. 25th, 2023 Already received • Listed on Euronext Paris (ADOC) • €95m raised since inception Free float • 13.9 shares outstanding 76,8% • $135m received from partnerships Soula Family
Slide 41: Summary
Summary • Adocia’s projects are based on 4 proprietary technologies: BioChaperone®, AdOral®, AdoShell®, AdoGel® • Adocia is seeking to license-out the assets from its well-advanced and diversified pipeline: • Key products in ongoing clinical trials: o BC Lispro: Phase 3 in China o BC Combo: positive
Slide 42: Thank you for your kind interest
Thank you for your kind interest 115 avenue Lacassagne 69003 Lyon – FRANCE Ph.:+33 4 72 610 610 contact@adocia.com